比索洛尔用于慢性阻塞性肺疾病急性加重高风险患者:BICS随机临床试验
BICS是一项在英国76个中心开展的双盲安慰剂对照随机临床试验,纳入有至少中度气流受限且过去12个月至少2次需口服糖皮质激素或抗生素治疗的COPD急性加重患者。比索洛尔组(n=261)与安慰剂组(n=258)的患者报告COPD急性加重率分别为2.03/年与2.01/年,调整后发生率比为0.97(95%CI 0.84-1.13;P=0.72),比索洛尔未减少需口服糖皮质激素或抗生素治疗的COPD急性加重。
要点
- 在COPD急性加重高风险患者中,比索洛尔组与安慰剂组的年加重率分别为2.03与2.01,调整后发生率比为0.97(95%CI 0.84-1.13;P=0.72)。
- 比索洛尔组严重不良事件发生率为14.5%(37/255),安慰剂组为14.3%(36/251),相对危险度为1.01(95%CI 0.62-1.66;P=0.96)。
- 比索洛尔未减少需口服糖皮质激素或抗生素治疗的COPD急性加重。
核心结论
- 在COPD急性加重高风险人群中,比索洛尔治疗未减少患者自我报告的需口服糖皮质激素或抗生素治疗的COPD急性加重次数。
研究设计与样本
- BICS为双盲安慰剂对照随机临床试验,在英国76个中心(45个初级保健诊所和31个二级诊所)开展。
- 纳入标准为:COPD患者,肺功能检查显示至少中度气流受限(FEV1/FVC<0.7;FEV1<80%预计值),且过去12个月内至少2次COPD急性加重接受口服糖皮质激素、抗生素或两者治疗。
- 患者随机分配至比索洛尔组(n=261)或安慰剂组(n=258);比索洛尔起始剂量为1.25 mg口服每日一次,按标准化方案在4次访视中根据耐受性滴定至最大剂量5 mg/d。
- 主要临床结局为1年治疗期间患者报告的需口服糖皮质激素、抗生素或两者治疗的COPD急性加重次数;安全性结局包括严重不良事件和不良反应。
主要发现
- 主要结局:比索洛尔组患者报告的需口服糖皮质激素、抗生素或两者治疗的COPD急性加重共526次,平均加重率为2.03/年;安慰剂组共513次,平均加重率为2.01/年;调整后发生率比为0.97(95%CI 0.84-1.13;P=0.72)。
- 严重不良事件:比索洛尔组255例中37例(14.5%)发生严重不良事件,安慰剂组251例中36例(14.3%)发生;相对危险度为1.01(95%CI 0.62-1.66;P=0.96)。
- 共有515例患者纳入分析(平均[SD]年龄68[7.9]岁;男性274例[53%];平均FEV1为50.1%),主要结局数据可获取514例(99.8%),371例(72.0%)继续服用研究药物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 尽管试验计划纳入1574例患者,但因COVID-19大流行,招募于2020年3月16日至2021年7月31日暂停。
- 两组各有2例患者在随机化后被排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Observational studies report that β-blocker use may be associated with reduced risk of COPD exacerbations. However, a recent trial reported that metoprolol did not reduce COPD exacerbations and increased COPD exacerbations requiring hospital admission. OBJECTIVE: To test whether bisoprolol decreased COPD exacerbations in people with COPD at high risk of exacerbations. DESIGN, SETTING, AND PARTICIPANTS: The Bisoprolol in COPD Study (BICS) was a double-blind placebo-controlled randomized clinical trial conducted in 76 UK sites (45 primary care clinics and 31 secondary clinics). Patients with COPD who had at least moderate airflow obstruction on spirometry (ratio of forced expiratory volume in the first second of expiration [FEV1] to forced vital capacity <0.7; FEV1 <80% predicted) and at least 2 COPD exacerbations treated with oral corticosteroids, antibiotics, or both in the prior 12 months were enrolled from October 17, 2018, to May 31, 2022. Follow-up concluded on April 18, 2023. INTERVENTIONS: Patients were randomly assigned to bisoprolol (n = 261) or placebo (n = 258). Bisoprolol was started at 1.25 mg orally daily and was titrated as tolerated during 4 sessions to a maximum dose of 5 mg/d, using a standardized protocol. MAIN OUTCOMES AND MEASURES: The primary clinical outcome was the number of patient-reported COPD exacerbations treated with oral corticosteroids, antibiotics, or both during the 1-year treatment period. Safety outcomes included serious adverse events and adverse reactions. RESULTS: Although the trial planned to enroll 1574 patients, recruitment was suspended from March 16, 2020, to July 31, 2021, due to the COVID-19 pandemic. Two patients in each group were excluded postrandomization. Among the 515 patients (mean [SD] age, 68 [7.9] years; 274 men [53%]; mean FEV1, 50.1%), primary outcome data were available for 514 patients (99.8%) and 371 (72.0%) continued taking the study drug. The primary outcome of patient-reported COPD exacerbations treated with oral corticosteroids, antibiotics, or both was 526 in the bisoprolol group, with a mean exacerbation rate of 2.03/y, vs 513 exacerbations in the placebo group, with a mean exacerbation rate of 2.01/y. The adjusted incidence rate ratio was 0.97 (95% CI, 0.84-1.13; P = .72). Serious adverse events occurred in 37 of 255 patients in the bisoprolol group (14.5%) vs 36 of 251 in the placebo group (14.3%; relative risk, 1.01; 95% CI, 0.62-1.66; P = .96). CONCLUSIONS AND RELEVANCE: Among people with COPD at high risk of exacerbation, treatment with bisoprolol did not reduce the number of self-reported COPD exacerbations requiring treatment with oral corticosteroids, antibiotics, or both. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN10497306.
引用
- Devereux G, Cotton S, Nath M, et al. Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial. JAMA. 2024. PMID: 38762800. doi:10.1001/jama.2024.8771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。